A comparative Study to Assess the Efficacy, Safety and Immunogenicity of YLB113 and Enbrel for the Treatment of Rheumatoid Arthritis

Trial Profile

A comparative Study to Assess the Efficacy, Safety and Immunogenicity of YLB113 and Enbrel for the Treatment of Rheumatoid Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors YL Biologics
  • Most Recent Events

    • 09 Oct 2017 Status changed from recruiting to completed.
    • 05 Oct 2017 The trial has been completed in Latvia (End date: 2017-08-02) according to European Clinical Trials Database record.
    • 30 Sep 2017 The trial has been completed in Bulgaria (End Date:2017-08-02).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top